Many patients with heart failure and a reduced left ventricular ejection fraction have iron deficiency, yet oral iron supplementation does not improve their exercise capacity. Read the full HEART-FID Research Summary by @robmentz et al.: https://t.co/Rp5redGiJB
Ferric Carboxymaltose in Heart Failure with Iron Deficiency.
Mentions
Extended reach
Total likes
Video views
Mentions per month
Aug 2023 – Oct 2025Where it's discussed
-
X / Twitter210 posts
-
News125 articles
-
Bluesky5 posts
-
Facebook3 posts
-
YouTube2 videos
-
Blogs2 articles
AI synopsis
What people are saying
The discussions center around the effectiveness of ferric carboxymaltose, with some posts noting that it 'did not significantly improve outcomes' compared to placebo, which resonates with comments questioning whether the therapy 'has died.' The tone is cautiously skeptical, using phrases like 'modest benefit' and 'no apparent difference,' contributing to a sentiment that while there's recognition of the study's importance, many feel it doesn't promise significant advancements in treatment.
The reactions are mixed regarding the effectiveness of ferric carboxymaltose, with some expressing skepticism about its benefits in comparison to placebo, while others acknowledge its safety.
Participants demonstrate moderate interest in the publication, as they discuss findings and implications without overwhelming enthusiasm.
Comments reference clinical trials and ongoing debates in the medical community, indicating a level of engagement with the topic.
The perceived impact is moderate; while there is recognition of the study's findings, many users highlight the lack of significant benefits.
Abstract in brief
- Ferric carboxymaltose therapy improves symptoms and quality of life in heart failure patients with iron deficiency, but more research on its effects on serious clinical events is necessary.
- In a double-blind trial, 3065 patients with reduced ejection fraction were split into two groups—one received ferric carboxymaltose, and the other a placebo, both along with standard treatment.
- Results showed that patients treated with ferric carboxymaltose had lower mortality rates and better 6-minute walk distance compared to the placebo group, while adverse events were similar in both groups.
- The study highlights the potential benefits of ferric carboxymaltose in managing heart failure symptoms and the safety of repeated dosing.
Top posts
Most liked on X and BlueskyIntravenous ferric carboxymaltose in heart failure with iron deficiency (FAIR-HF2 DZHK05 trial): Sex-specific outcomes This analysis indicates relevant differential efficacy of intravenous iron in heart failure across both sexes. While men receiving ferric carboxymaltose https://t.co/3FhXoCUy15
Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency - The FAIR-HF2 DZHK05 Randomized Clinical Trial Late-breaker @ACCinTouch and simultaneously published in @JAMA_current https://t.co/yMtVDAjOa1 https://t.co/BDDnSv5S3a
3. Ferric Carboxymaltose in Heart Failure with Iron Deficiency https://t.co/Rp5redGiJB #cardiology https://t.co/4dw8GbvYlO
Ferric Carboxymaltose in HF with Iron Deficiency
Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency The FAIR-HF2 DZHK05 Randomized Clinical Trial Ferric carboxymaltose was well tolerated, but did not significantly improve outcomes in heart failure and iron deficiency. https://t.co/fHd3yMpqNO
All mentions
iv Iron in Heart Failure - Prof. Robert Mentz, Prof. Hossein Ardehali, Prof. Paul Kalra
ECLS in Cardiogenic Shock: Recent Clinical Trial Insights
This week’s podcast discusses ECLS and its unclear effect on survival rates in cardiogenic shock related to heart attacks. Key trials like ECLSSHOCK and FIRE are analyzed, focusing on outcomes and complications observed…
New from #Transfusion Evidence Library: Intravenous ferric carboxymaltose in heart failure with iron deficiency (FAIR-HF2 DZHK05 trial): Sex-specific outcomes by Karakas et al. www.transfusionevidencelibrary.com/alerts/artic... #MedSky
Ferric Carboxymaltose in Heart Failure With Iron Deficiency https://t.co/d3NgV0aIB4
Ferric Carboxymaltose in Heart Failure With Iron Deficiency https://t.co/2Wkady5eDV
Ferric Carboxymaltose in Heart Failure With Iron Deficiency—Reply https://t.co/vaBsHZASLp
Ferric Carboxymaltose in Heart Failure With Iron Deficiency #science #publication #research #publications https://t.co/VHgLJIpDTi
Ferric Carboxymaltose in Heart Failure With Iron Deficiency #science #publication #research #publications https://t.co/6UOPGtQ4Ss
Ferric Carboxymaltose in Heart Failure With Iron Deficiency—Reply #science #publication #research #publications https://t.co/eew8CNgUMy
RT @soniya7ab: IV Ferric Carboxymaltose in Heart Failure with Iron Deficiency https://t.co/sUDqew2tWM
RT @drbennisahmed: Intravenous ferric carboxymaltose in heart failure with iron deficiency (FAIR-HF2 DZHK05 trial): Sex-specific outcomes…
RT @drbennisahmed: Intravenous ferric carboxymaltose in heart failure with iron deficiency (FAIR-HF2 DZHK05 trial): Sex-specific outcomes…
RT @drbennisahmed: Intravenous ferric carboxymaltose in heart failure with iron deficiency (FAIR-HF2 DZHK05 trial): Sex-specific outcomes…
RT @drbennisahmed: Intravenous ferric carboxymaltose in heart failure with iron deficiency (FAIR-HF2 DZHK05 trial): Sex-specific outcomes…
RT @drbennisahmed: Intravenous ferric carboxymaltose in heart failure with iron deficiency (FAIR-HF2 DZHK05 trial): Sex-specific outcomes…
RT @drbennisahmed: Intravenous ferric carboxymaltose in heart failure with iron deficiency (FAIR-HF2 DZHK05 trial): Sex-specific outcomes…
IV Ferric Carboxymaltose in Heart Failure with Iron Deficiency https://t.co/sUDqew2tWM
RT @drbennisahmed: Intravenous ferric carboxymaltose in heart failure with iron deficiency (FAIR-HF2 DZHK05 trial): Sex-specific outcomes…
RT @drbennisahmed: Intravenous ferric carboxymaltose in heart failure with iron deficiency (FAIR-HF2 DZHK05 trial): Sex-specific outcomes…
' Intravenous ferric carboxymaltose in heart failure with iron deficiency ' https://t.co/P3vGTlbNnv
RT @drbennisahmed: Intravenous ferric carboxymaltose in heart failure with iron deficiency (FAIR-HF2 DZHK05 trial): Sex-specific outcomes…
RT @drbennisahmed: Intravenous ferric carboxymaltose in heart failure with iron deficiency (FAIR-HF2 DZHK05 trial): Sex-specific outcomes…
RT @drbennisahmed: Intravenous ferric carboxymaltose in heart failure with iron deficiency (FAIR-HF2 DZHK05 trial): Sex-specific outcomes…
RT @drbennisahmed: Intravenous ferric carboxymaltose in heart failure with iron deficiency (FAIR-HF2 DZHK05 trial): Sex-specific outcomes…
RT @drbennisahmed: Intravenous ferric carboxymaltose in heart failure with iron deficiency (FAIR-HF2 DZHK05 trial): Sex-specific outcomes…
RT @drbennisahmed: Intravenous ferric carboxymaltose in heart failure with iron deficiency (FAIR-HF2 DZHK05 trial): Sex-specific outcomes…
RT @drbennisahmed: Intravenous ferric carboxymaltose in heart failure with iron deficiency (FAIR-HF2 DZHK05 trial): Sex-specific outcomes…
RT @drbennisahmed: Intravenous ferric carboxymaltose in heart failure with iron deficiency (FAIR-HF2 DZHK05 trial): Sex-specific outcomes…
RT @drbennisahmed: Intravenous ferric carboxymaltose in heart failure with iron deficiency (FAIR-HF2 DZHK05 trial): Sex-specific outcomes…
RT @drbennisahmed: Intravenous ferric carboxymaltose in heart failure with iron deficiency (FAIR-HF2 DZHK05 trial): Sex-specific outcomes…
RT @drbennisahmed: Intravenous ferric carboxymaltose in heart failure with iron deficiency (FAIR-HF2 DZHK05 trial): Sex-specific outcomes…
Intravenous ferric carboxymaltose in heart failure with iron deficiency (FAIR-HF2 DZHK05 trial): Sex-specific outcomes This analysis indicates relevant differential efficacy of intravenous iron in heart failure across both sexes. While men receiving ferric carboxymaltose https://t.co/3FhXoCUy15
Intravenous ferric carboxymaltose in heart failure with iron deficiency (FAIR‐HF2 DZHK05 trial): Sex‐specific outcomes https://t.co/kjN93NQUWy
RT @drbennisahmed: Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency The FAIR-HF2 DZHK05 Randomized Clinical Trial F…
RT @drbennisahmed: Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency The FAIR-HF2 DZHK05 Randomized Clinical Trial F…
RT @drbennisahmed: Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency The FAIR-HF2 DZHK05 Randomized Clinical Trial F…
RT @drbennisahmed: Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency The FAIR-HF2 DZHK05 Randomized Clinical Trial F…
Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency The FAIR-HF2 DZHK05 Randomized Clinical Trial Ferric carboxymaltose was well tolerated, but did not significantly improve outcomes in heart failure and iron deficiency. https://t.co/fHd3yMpqNO
RT @SubodhVermaMD: Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency https://t.co/WVGH8qHDhl
Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency https://t.co/WVGH8qHDhl
RT @abdelhamed012: Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency https://t.co/1mtWJo3API
Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency https://t.co/1mtWJo3API
Ferric carboxymaltose did not significantly reduce the time to first heart failure hospitalization or cardiovascular death, nor the total heart failure hospitalizations, compared with placebo. #MedSky #CardioSky https://ja.ma/4l0Tvtz
RT @etevalf: Y que esto se publique justo cuando salen los genéricos del Fe carboximaltosa... Otra casualidad más.
RT @etevalf: Y que esto se publique justo cuando salen los genéricos del Fe carboximaltosa... Otra casualidad más.
RT @etevalf: Y que esto se publique justo cuando salen los genéricos del Fe carboximaltosa... Otra casualidad más.
RT @etevalf: Y que esto se publique justo cuando salen los genéricos del Fe carboximaltosa... Otra casualidad más.
Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency https://t.co/ak6TFPBato
Y que esto se publique justo cuando salen los genéricos del Fe carboximaltosa... Otra casualidad más.
"Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency." Publié ce jour dans @jama.com. #MedSky jamanetwork.com/journals/jam...
Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency https://t.co/HU47rwchku
New from the #Transfusion Evidence Alert: Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency: The FAIR-HF2 DZHK05 Randomized Clinical Trial by Anker et al. www.transfusionevidencelibrary.com/alerts/artic... #MedSky
In the HEART-FID trial, IV ferric carboxymaltose reduced symptoms—but did not significantly impact death, HF hospitalization, or walk distance compared to placebo. Dive in further: https://t.co/DZ4FcOHFPJ #CardioTwitter #HeartFailure
Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency https://t.co/ngScIerSEs
RT @drbennisahmed: Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency The FAIR-HF2 DZHK05 Randomized Clinical Trial F…
RT @drbennisahmed: Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency The FAIR-HF2 DZHK05 Randomized Clinical Trial F…
RT @drbennisahmed: Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency The FAIR-HF2 DZHK05 Randomized Clinical Trial F…
RT @drbennisahmed: Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency The FAIR-HF2 DZHK05 Randomized Clinical Trial F…
Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency The FAIR-HF2 DZHK05 Randomized Clinical Trial Ferric carboxymaltose was well tolerated, but did not significantly improve outcomes compared with placebo in patients with HF and ID https://t.co/fHd3yMoSYg
RT @talhakhawaja_: Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency - The FAIR-HF2 DZHK05 Randomized Clinical Trial…
Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency: The FAIR-HF2 DZHK05 Randomized Clinical Trial | Heart Failure | JAMA | JAMA Network https://t.co/3yFLi0TuEU
Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency https://t.co/JF49eULeXA Ferric carboxymaltose was well tolerated but did NOT significantly improve outcomes compared with placebo in heart failure and iron deficiency @AskDrShashank @DrAsifQasim
RT @talhakhawaja_: Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency - The FAIR-HF2 DZHK05 Randomized Clinical Trial…
Any benefit of Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency https://t.co/MLjIKP2tVB
RT @talhakhawaja_: Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency - The FAIR-HF2 DZHK05 Randomized Clinical Trial…
RT @talhakhawaja_: Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency - The FAIR-HF2 DZHK05 Randomized Clinical Trial…
Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency: The FAIR-HF2 DZHK05 Randomized Clinical Trial | Heart Failure | JAMA | JAMA Network https://t.co/KbzvryyhSd
RT @talhakhawaja_: Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency - The FAIR-HF2 DZHK05 Randomized Clinical Trial…
Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency https://t.co/VcCUhlegeH
RT @talhakhawaja_: Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency - The FAIR-HF2 DZHK05 Randomized Clinical Trial…
RT @talhakhawaja_: Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency - The FAIR-HF2 DZHK05 Randomized Clinical Trial…
RT @talhakhawaja_: Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency - The FAIR-HF2 DZHK05 Randomized Clinical Trial…
RT @talhakhawaja_: Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency - The FAIR-HF2 DZHK05 Randomized Clinical Trial…
RT @talhakhawaja_: Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency - The FAIR-HF2 DZHK05 Randomized Clinical Trial…
RT @JAMA_current: Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency: The FAIR-HF2 DZHK05 Trial presented today at #AC…
RT @JAMA_current: Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency: The FAIR-HF2 DZHK05 Trial presented today at #AC…
RT @talhakhawaja_: Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency - The FAIR-HF2 DZHK05 Randomized Clinical Trial…
RT @drbennisahmed: Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency The FAIR-HF2 DZHK05 Randomized Clinical #ACC25…
RT @talhakhawaja_: Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency - The FAIR-HF2 DZHK05 Randomized Clinical Trial…
RT @talhakhawaja_: Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency - The FAIR-HF2 DZHK05 Randomized Clinical Trial…
RT @talhakhawaja_: Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency - The FAIR-HF2 DZHK05 Randomized Clinical Trial…
RT @talhakhawaja_: Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency - The FAIR-HF2 DZHK05 Randomized Clinical Trial…
RT @SAC_54:
RT @talhakhawaja_: Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency - The FAIR-HF2 DZHK05 Randomized Clinical Trial…
RT @talhakhawaja_: Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency - The FAIR-HF2 DZHK05 Randomized Clinical Trial…
RT @talhakhawaja_: Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency - The FAIR-HF2 DZHK05 Randomized Clinical Trial…
RT @JAMA_current: Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency: The FAIR-HF2 DZHK05 Trial presented today at #AC…
RT @talhakhawaja_: Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency - The FAIR-HF2 DZHK05 Randomized Clinical Trial…
RT @talhakhawaja_: Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency - The FAIR-HF2 DZHK05 Randomized Clinical Trial…
RT @talhakhawaja_: Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency - The FAIR-HF2 DZHK05 Randomized Clinical Trial…
RT @talhakhawaja_: Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency - The FAIR-HF2 DZHK05 Randomized Clinical Trial…
Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency - The FAIR-HF2 DZHK05 Randomized Clinical Trial Late-breaker @ACCinTouch and simultaneously published in @JAMA_current https://t.co/yMtVDAjOa1 https://t.co/BDDnSv5S3a
Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency: The FAIR-HF2 DZHK05 Trial presented today at #ACC25, is free to read online from JAMA. ➡️ https://t.co/SlhCoujeal https://t.co/383GwepKHt
Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency: The FAIR-HF2 DZHK05 Trial presented today at #ACC25, is free to read online from @JAMA_current. ➡️ https://t.co/jaIZWlQEG1 https://t.co/kf14135RVv
Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency: The FAIR-HF2 DZHK05 Randomized Clinical Trial | Heart Failure | JAMA | JAMA Network https://t.co/Luno2PuTQd
Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency The FAIR-HF2 DZHK05 Randomized Clinical #ACC25 Ferric carboxymaltose was well tolerated, but did not significantly improve outcomes compared with placebo in patients with HF and ID https://t.co/fHd3yMoSYg
Ferric carboxymaltose did not significantly reduce the time to first heart failure hospitalization or cardiovascular death, nor the total heart failure hospitalizations, compared with placebo. #ACC25 https://ja.ma/4j6M5nG
https://t.co/Pm0FrFuyj7
鉄欠乏症を伴う心不全における第二鉄カルボキシマルトース | ニューイングランド・ジャーナル・オブ・メディシン https://t.co/jkHg5olNgB
From last year, this meta-analysis of 4501 HF pts in 3 RCTs of FCM vs placebo: FCM reduced hospitalization rates, no improved survival. Efficacy of ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis https://t.co/NeERXtsYGp
RT @drbennisahmed: Efficacy of ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis intra…
Efficacy of ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis intravenous FCM associated with reduced risk of hospital admissions for HF and CV causes, with no apparent effect on mortality https://t.co/2jcjzHJp2r https://t.co/i9JMTuKYrR
Discover how ferric carboxymaltose can reduce symptoms and improve quality of life in heart failure patients with iron deficiency. Dive into the full study for detailed insights: https://t.co/aoVWTPLc17 #HeartFailure #IronDeficiency #MedicalResearch
Ferric Carboxymaltose in Heart Failure with Iron Deficiency | New England Journal of Medicine https://t.co/EF0baCfkIl
【文献メモ】(特集:心不全と鉄) Efficacy of ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis (Eur. Heart J. 2023, 44(48), 5077-5091.) https://t.co/BichM3MtqU
RT @GRUPOCRONOSSEF1:
RT @dora_ph: あれ?あれ?鉄欠乏のあるHFrEF患者に対する鉄補充って超有用ってふんわり思っていたけど、そんなことはないのか。なんでそう思っていたのだろう?? https://t.co/w8W2Zzypa0
あれ?あれ?鉄欠乏のあるHFrEF患者に対する鉄補充って超有用ってふんわり思っていたけど、そんなことはないのか。なんでそう思っていたのだろう?? https://t.co/w8W2Zzypa0
RT @richardbuka: 14/ IV iron in heart failure made no difference to a composite of death, hospitalizations for heart failure, or 6-minute w…
RT @MaryamBMD: 11/ Results of Heart-FID trial showed: Modest benefit of ferrous carboxymaltose in all-cause mortality☠️, HF hospitalization…
11/ Results of Heart-FID trial showed: Modest benefit of ferrous carboxymaltose in all-cause mortality☠️, HF hospitalization
#117 Ferric Carboxymaltose in Heart Failure with Iron Deficiency N Engl J Med 2023;389:975-86. HEART-FID試験 鉄欠乏性貧血を伴う心不全でカルボキシマルトース第二鉄を投与した場合、プラセボと比較して、死亡、心不全による入院、6 分間歩行距離の階層的複合エンドポイントは改善しなかった
14/ IV iron in heart failure made no difference to a composite of death, hospitalizations for heart failure, or 6-minute walk distance. More lack of evidence for tangible benefits of IV iron despite widespread use in many situations. https://t.co/bQezfp4xwE
RT @IronBiologyBot: Ferric Carboxymaltose in Heart Failure with Iron Deficiency https://t.co/wgnY5QumiD #IronBiology #BioIron #Iron
RT @IronBiologyBot: Ferric Carboxymaltose in Heart Failure with Iron Deficiency https://t.co/fwEanuI4sA #IronBiology #BioIron #Iron
RT @IronBiologyBot: Ferric Carboxymaltose in Heart Failure with Iron Deficiency https://t.co/1Sb5wecBTj #IronBiology #BioIron #Iron
RT @IronBiologyBot: Ferric Carboxymaltose in Heart Failure with Iron Deficiency. Reply https://t.co/AVpeRnYZOG #IronBiology #BioIron #Iron
RT @NEJM: 3. Ferric Carboxymaltose in Heart Failure with Iron Deficiency https://t.co/Rp5redGiJB #cardiology https://t.co/4dw8GbvYlO
RT @NEJM: 3. Ferric Carboxymaltose in Heart Failure with Iron Deficiency https://t.co/Rp5redGiJB #cardiology https://t.co/4dw8GbvYlO
RT @NEJM: 3. Ferric Carboxymaltose in Heart Failure with Iron Deficiency https://t.co/Rp5redGiJB #cardiology https://t.co/4dw8GbvYlO
RT @NEJM: 3. Ferric Carboxymaltose in Heart Failure with Iron Deficiency https://t.co/Rp5redGiJB #cardiology https://t.co/4dw8GbvYlO
Sin diferencias aparentes con placebo Ferric Carboxymaltose in Heart Failure with Iron Deficiency | NEJM https://t.co/TKH9vniyKJ
@DrLindaDykes https://t.co/D4Gx2wNN6D
RT @HanchateShivani: 5/ but no benefit ➡️
5/ but no benefit ➡️
https://t.co/8sIHgRJVmt
¿Con este estudio podríamos decir que la terapia de reemplazo de hierro en pacientes con falla cardiaca ha muerto? Podemos tener muchas teorías sobre la razón de ser un estudio negativo, generar hipótesis, que deben probarse. ¿Alguna crítica al diseño? https://t.co/y35dAfvmPK
In a double-blind, randomized trial, ferric carboxymaltose didn't outperform a placebo in improving outcomes for HF patients with ID. The study analyzed death rates, hospitalizations, and 6-minute walk distance changes. Review data: https://t.co/B0uqwFQQLP Source: NEJM
RT @U40HF: #HEART_FID https://t.co/VkQFrK2OYg
#HEART_FID https://t.co/VkQFrK2OYg
RT @RevistaMFSamfyc: Carboximaltosa férrica en insuficiencia cardiaca con déficit de hierro https://t.co/YC926kcazh PMID 19920054
RT @vic_pallares: Ferric Carboxymaltose in HF with Iron Deficiency
RT @vic_pallares: Ferric Carboxymaltose in HF with Iron Deficiency
RT @vic_pallares: Ferric Carboxymaltose in HF with Iron Deficiency
RT @vic_pallares: Ferric Carboxymaltose in HF with Iron Deficiency
RT @vic_pallares: Ferric Carboxymaltose in HF with Iron Deficiency
RT @vic_pallares: Ferric Carboxymaltose in HF with Iron Deficiency
RT @vic_pallares: Ferric Carboxymaltose in HF with Iron Deficiency
RT @vic_pallares: Ferric Carboxymaltose in HF with Iron Deficiency
RT @vic_pallares: Ferric Carboxymaltose in HF with Iron Deficiency
RT @vic_pallares: Ferric Carboxymaltose in HF with Iron Deficiency
RT @vic_pallares: Ferric Carboxymaltose in HF with Iron Deficiency
RT @vic_pallares: Ferric Carboxymaltose in HF with Iron Deficiency
RT @vic_pallares: Ferric Carboxymaltose in HF with Iron Deficiency
RT @vic_pallares: Ferric Carboxymaltose in HF with Iron Deficiency
Ferric Carboxymaltose in HF with Iron Deficiency
Carboximaltosa férrica en insuficiencia cardiaca con déficit de hierro https://t.co/YC926kcazh PMID 19920054
Ferric #Carboxymaltose in #HeartFailure with #IronDeficiency This highlights how treating iron deficiency parenterally can help even heart failure
RT @NEJM: 3. Ferric Carboxymaltose in Heart Failure with Iron Deficiency https://t.co/Rp5redGiJB #cardiology https://t.co/4dw8GbvYlO
RT @NEJM: 3. Ferric Carboxymaltose in Heart Failure with Iron Deficiency https://t.co/Rp5redGiJB #cardiology https://t.co/4dw8GbvYlO
RT @NEJM: 3. Ferric Carboxymaltose in Heart Failure with Iron Deficiency https://t.co/Rp5redGiJB #cardiology https://t.co/4dw8GbvYlO
RT @NEJM: 3. Ferric Carboxymaltose in Heart Failure with Iron Deficiency https://t.co/Rp5redGiJB #cardiology https://t.co/4dw8GbvYlO
RT @NEJM: 3. Ferric Carboxymaltose in Heart Failure with Iron Deficiency https://t.co/Rp5redGiJB #cardiology https://t.co/4dw8GbvYlO
RT @NEJM: 3. Ferric Carboxymaltose in Heart Failure with Iron Deficiency https://t.co/Rp5redGiJB #cardiology https://t.co/4dw8GbvYlO
3. Ferric Carboxymaltose in Heart Failure with Iron Deficiency https://t.co/Rp5redGiJB #cardiology https://t.co/4dw8GbvYlO
Ferric Carboxymaltose in Heart Failure with Iron Deficiency | NEJM https://t.co/v6RxjPjyZS
RT @FAPsGal:
RT @FAPsGal:
RT @FAPsGal:
RT @FAPsGal:
RT @FAPsGal:
RT @gunnar_heine: HEART-FID, the largest iv iron trial ever in HF! This Week in @NEJM - Next Week in MARKUS@HOMe! We are honored to host Pr…
RT @JurgaTomek: Is anyone else surprised by the neutral results in HEART-FID? This goes against studies like AFFIRM-AHF, FAIR-HF, etc. Lik…
RT @NEJM: Many patients with heart failure and a reduced left ventricular ejection fraction have iron deficiency, yet oral iron supplementa…
RT @NEJM: Many patients with heart failure and a reduced left ventricular ejection fraction have iron deficiency, yet oral iron supplementa…
RT @mzkhalil: Ferric Carboxymaltose in Heart Failure with Iron Deficiency | NEJM No benefits of iron therapy in patients with HFrEF…! ht…
RT @NEJM: Many patients with heart failure and a reduced left ventricular ejection fraction have iron deficiency, yet oral iron supplementa…
Is anyone else surprised by the neutral results in HEART-FID? This goes against studies like AFFIRM-AHF, FAIR-HF, etc. Likely reasons: pts were ambulatory, COVID-19 pandemic interference, higher use of ARNi and SLGT2i. Thoughts? #TwitterRx #CardioTwitter https://t.co/zF7Ru7wzYr
RT @NEJM: Many patients with heart failure and a reduced left ventricular ejection fraction have iron deficiency, yet oral iron supplementa…
RT @gunnar_heine: HEART-FID, the largest iv iron trial ever in HF! This Week in @NEJM - Next Week in MARKUS@HOMe! We are honored to host Pr…
RT @mzkhalil: Ferric Carboxymaltose in Heart Failure with Iron Deficiency | NEJM No benefits of iron therapy in patients with HFrEF…! ht…
RT @NEJM: Many patients with heart failure and a reduced left ventricular ejection fraction have iron deficiency, yet oral iron supplementa…
RT @mzkhalil: Ferric Carboxymaltose in Heart Failure with Iron Deficiency | NEJM No benefits of iron therapy in patients with HFrEF…! ht…
Ferric Carboxymaltose in Heart Failure with Iron Deficiency | NEJM https://t.co/b1gpgnGVvZ
RT @NEJM: Many patients with heart failure and a reduced left ventricular ejection fraction have iron deficiency, yet oral iron supplementa…
RT @gunnar_heine: HEART-FID, the largest iv iron trial ever in HF! This Week in @NEJM - Next Week in MARKUS@HOMe! We are honored to host Pr…
RT @gunnar_heine: HEART-FID, the largest iv iron trial ever in HF! This Week in @NEJM - Next Week in MARKUS@HOMe! We are honored to host Pr…
RT @NEJM: Many patients with heart failure and a reduced left ventricular ejection fraction have iron deficiency, yet oral iron supplementa…
RT @NEJM: Many patients with heart failure and a reduced left ventricular ejection fraction have iron deficiency, yet oral iron supplementa…
RT @NEJM: Many patients with heart failure and a reduced left ventricular ejection fraction have iron deficiency, yet oral iron supplementa…
RT @gunnar_heine: HEART-FID, the largest iv iron trial ever in HF! This Week in @NEJM - Next Week in MARKUS@HOMe! We are honored to host Pr…
RT @NEJM: Many patients with heart failure and a reduced left ventricular ejection fraction have iron deficiency, yet oral iron supplementa…
HEART-FID, the largest iv iron trial ever in HF! This Week in @NEJM - Next Week in MARKUS@HOMe! We are honored to host Prof. @robmentz together with Prof. Kalra and @ArdehaliHossein next Friday for our "Global Iron Summit" @MarcusSaemann @floriancustodis https://t.co/LPHdCV06yX https://t.co/KtcCTeZFZ4
RT @NEJM: Many patients with heart failure and a reduced left ventricular ejection fraction have iron deficiency, yet oral iron supplementa…
RT @NEJM: Many patients with heart failure and a reduced left ventricular ejection fraction have iron deficiency, yet oral iron supplementa…
RT @NEJM: Many patients with heart failure and a reduced left ventricular ejection fraction have iron deficiency, yet oral iron supplementa…
RT @NEJM: Many patients with heart failure and a reduced left ventricular ejection fraction have iron deficiency, yet oral iron supplementa…
RT @NEJM: Many patients with heart failure and a reduced left ventricular ejection fraction have iron deficiency, yet oral iron supplementa…
RT @NEJM: Many patients with heart failure and a reduced left ventricular ejection fraction have iron deficiency, yet oral iron supplementa…
RT @NEJM: Many patients with heart failure and a reduced left ventricular ejection fraction have iron deficiency, yet oral iron supplementa…
RT @NEJM: Many patients with heart failure and a reduced left ventricular ejection fraction have iron deficiency, yet oral iron supplementa…
RT @NEJM: Many patients with heart failure and a reduced left ventricular ejection fraction have iron deficiency, yet oral iron supplementa…
RT @NEJM: Many patients with heart failure and a reduced left ventricular ejection fraction have iron deficiency, yet oral iron supplementa…
RT @NEJM: Many patients with heart failure and a reduced left ventricular ejection fraction have iron deficiency, yet oral iron supplementa…
RT @NEJM: Many patients with heart failure and a reduced left ventricular ejection fraction have iron deficiency, yet oral iron supplementa…
Many patients with heart failure and a reduced left ventricular ejection fraction have iron deficiency, yet oral iron supplementation does not improve their exercise capacity. Read the full HEART-FID Research Summary by @robmentz et al.: https://t.co/Rp5redGiJB
Ferric carboxymaltose does not improve heart failure with iron deficiency https://t.co/d3jPGE7Lo8
Ferric Carboxymaltose in Heart Failure with Iron Deficiency there was no apparent difference between ferric carboxymaltose and placebo with respect to the hierarchical composite of death, hospitalizations for heart failure, or 6-minute https://t.co/TRKJ1z6Jrf
RT @mzkhalil: Ferric Carboxymaltose in Heart Failure with Iron Deficiency | NEJM No benefits of iron therapy in patients with HFrEF…! ht…
RT @mzkhalil: Ferric Carboxymaltose in Heart Failure with Iron Deficiency | NEJM No benefits of iron therapy in patients with HFrEF…! ht…
RT @mzkhalil: Ferric Carboxymaltose in Heart Failure with Iron Deficiency | NEJM No benefits of iron therapy in patients with HFrEF…! ht…
RT @mzkhalil: Ferric Carboxymaltose in Heart Failure with Iron Deficiency | NEJM No benefits of iron therapy in patients with HFrEF…! ht…
RT @ddunguh: Ferric Carboxymaltose in Heart Failure with Iron Deficiency https://t.co/8wFIdOJSkW @rkalyes1
RT @ddunguh: Ferric Carboxymaltose in Heart Failure with Iron Deficiency https://t.co/8wFIdOJSkW @rkalyes1
RT @ddunguh: Ferric Carboxymaltose in Heart Failure with Iron Deficiency https://t.co/8wFIdOJSkW @rkalyes1
RT @ddunguh: Ferric Carboxymaltose in Heart Failure with Iron Deficiency https://t.co/8wFIdOJSkW @rkalyes1
RT @ddunguh: Ferric Carboxymaltose in Heart Failure with Iron Deficiency https://t.co/8wFIdOJSkW @rkalyes1
RT @ddunguh: Ferric Carboxymaltose in Heart Failure with Iron Deficiency https://t.co/8wFIdOJSkW @rkalyes1
RT @ddunguh: Ferric Carboxymaltose in Heart Failure with Iron Deficiency https://t.co/8wFIdOJSkW @rkalyes1
Ferric Carboxymaltose in Heart Failure with Iron Deficiency https://t.co/8wFIdOJSkW @rkalyes1
【RCT】鉄欠乏を伴うLVEF40%以下の外来心不全患者に対する標準治療へのカルボキシマルトース第二鉄の追加は、プラセボの追加と比較して、死亡、心不全入院、6分間歩行距離の階層的複合転帰を改善させなかった。 #ペ読 https://t.co/AWPqjm9KMM
This is the link to the @NEJM paper of @robmentz providing a large cohort of ambulatory pts with #HFrEF and #iron_deficiency where #Ferric_cardoxy_maltose did NOT reduce the hierarchical composite of death, HHF, or 6-MWT @BSHeartFailure #CardioTwitter https://t.co/EBZS7UAfxe
Ferric Carboxymaltose in Heart Failure with Iron Deficiency #IronBiology #BioIron #Iron https://t.co/JaNqrekJ86
Kudos @robmentz! Proud to be part of the HEART-FID Team- the trial confirms safety of FCM + modest benefit in hierarchical endpoint (p=0.019), complementing a wealth of data supporting the role of IV iron in improving QOL and functional capacity in HFrEF. https://t.co/YRpqAUQGo3 https://t.co/6JFO1kuuHK